OZAGREL HYDROCHLORIDE IS A SELECTIVE THROMBOXANE A2 SYNTHETASE ENZYME INHIBITORS. OZAGREL HYDROCHLORIDE DISPLAYS A POWERFUL INHIBITORY ACTION ON THROMBOXANE (TX) SYNTHETASE. BY SELECTIVELY IHIBITING TX SYNTHETASE,THE DRUG SUPRESSES THE PRODUCTION OF TXA2, WHICH ACT TO AGGRAVATE AIRWAY OBSTRUCTION & ANAHYLAXIS.
INDICATIONS : TREATMENT OF BRONCHIAL ASTHAM, ACUTE ISCHAEMIC LACUNAR INFARCTS.
CONTRAINDICATIONS : HYPERSENSITIVITY, IN CHILDREN.
SAFETY PROFILE :SHOULD BE ADMINISTER WITH CARE IN PATIENTS WITH HEMORRHAGE. THERE IS A POSSIBILITY OF AGGRAVATION OF HEMORRHAGE IN SUCH PATIENTS. UNLIKE BRONCHODILATORS OR STEROIDS, OZAGREL HYDROCHORIDE IS NOT INDICATED FOR RELIEVING ATTACKS WHICH HAVE ALREADY OCCURRED. THIS MUST BE EXPLAINED CAREFULLY TO THE PATIENTS. IF MAJOR ATTACK OCCUR IN BRONCHIAL ASTHMA PATIENTS WHILE OZAGREL HYDROCHLORIDE IS ADMINISTERED, IT IS NECESSARY TO ADMINISTER BROHCHODILATORS OR STEROIDS. IF STEROID DOSES ARE TO BE REDUCED AS OZAGREL HYDROCHLORIDE IS ADMINISTERED IN PATIENTS UNDERGOING LONG TERM STEROID THERAPY, THE DOSES REDUCTION MUST BE GRADUAL AND ADEQUATELY SUPERVISED. IN PATIENTS TO WHOM THE MAINTENANCE DOSE OF STEROIDS CAN BE REDUCED AS OZAGREL HYDROCHLORIDE IS ADMINISTERED, CARE MUST BE TAKEN WHEN THE DRUG IS DISCONTINUED, AS THERE IS A RISK OF RECURRENCE OF UNDERLYING DISEASE. CAUTION IS ADVISED TO AVOID ITS PROLONGED USE. THE SAFETY OF OZAGREL HYDROCHLORIDE IN PRAGNANT WOMEN HAS NOT BE ESTABLISHED. NURSING MOTHER SHOULD NOT BE GIVEN LARGE DOSES OF OZAGREL HYDROCHLORIDE.
ADVERSE EFFECTS :INCREASE OF AST (GOT) AND ALT (GPT) LEVELS, NAUSEA, PRURITUS, RASFI, GASTRIC DISCOMFORT, ABDOMINAL DISCOMFORT, AND BLEEDING TENDENCY, THROMBOCYTOPENIA, HEADACHE, FEVER, NUMBNESS,MALAISE, LEG PAIN, DIZZINESS, SLEEPINESS, AND ARTHRALGIA
DRUG INTERACTIONS : CAUTION IS ADVISED WHEN OZAGREL HYDROCHLORIDE IS COADMINISTERED WITH THE DRUGS LIKE TICLOPIDINE, UROKINASE, HEPARIN AND WARFARIN. BY COADMINISTRATON WITH THESE DRUGS, BLEEDING TENDENCY MAY BE ENHANCED. OZAGREL HYDROCHLORIDE SUPPRESSES THE FUNCTION OF PLATELET AGGREGATION, SO WHEN COADMINISTERED WITH THESE DRUGS THERE IS A RISK OF ENHANCING ACTIONS. SO SUFFTICENT OBSERVATION AND CARE SUCH AS REOULATION OF THE DOSAGE SHOUKD BE TAKEN.
DOSAGE :400MG IN TWO DIVIDED DOSES (AFTER BREAKFAST AND BEFORE BED TIME) MAY BE ADJUSTED ACCORDING TO PATIENT CONDITION AND AGE.
ACUTE ISCHAEMIC LACUNAR INFARCTS:
THE PRESENT STUDY WAS DESIGNED TO EXAMINE THE EFFECTS OF SODIUM OZAGREL ON HEMOSTATIC MARKERS AND CEREBRAL BLOOD FLOW IN LACUNAR INFARCTION. TEN CASES OF LACUNAR INFARCTION IN WHICH SODIUM OZAGREL WAS GIVEN (ADMINISTERED GROUP), 10 CASES OF LACUNAR INFARCTION IN WHICH SODIUM OZAGREL WAS NOT GIVEN (NONADMINISTERED GROUP), AND 10 AGE-MATCHED CONTROLS IN WHICH CEREBROVASCULAR DISEASES WERE ABSENT BUT RISK FACTORS WERE SIMILAR TO THOSE OF THE PATIENTS (CONTROL GROUP) WERE STUDIED. INTRAVENOUS INFUSION OF 80 MG OF SODIUM OZAGREL WAS DONE TWICE A DAY FOR 2 WEEKS. PLATELET FACTOR 4, BETA-THROMBOGLOBULIN, AND FIBRINOPEPTIDE A WERE SIGNIFICANTLY HIGHER IN THE ADMINISTERED AND NONADMINISTERED GROUPS THAN IN THE CONTROL GROUP AT THE TIME OF ADMISSION. PLATELET FACTOR 4, BETA-THROMBOGLOBULIN, FIBRINOPEPTIDE A, AND THROMBOXANE B2 WERE DECREASED SIGNIFICANTLY BY THE ADMINISTRATION OF SODIUM OZAGREL. THE BLOOD FLOW IN THE CEREBRAL CORTEX WAS SIGNIFICANTLY LOWER IN THE ADMINISTERED AND NONADMINISTERED GROUPS THAN IN THE CONTROL GROUP. THE BLOOD FLOWS AROUND THE INFARCTED AREA, IN THE CEREBRAL CORTEX, AND IN THE CEREBRAL WHITE MATTER WERE SIGNIFICANTLY INCREASED BY THE ADMINISTRATION OF SODIUM OZAGREL. SODIUM OZAGREL IS CONSIDERED TO DECREASE PLATELET AGGREGATION AND INCREASE CEREBRAL BLOOD FLOW BY DECREASING THROMBOXANE A2, WHICH HAS A PLATELET-AGGREGATING AND A VASOCONSTRICTING ACTION. SODIUM OZAGREL IS CONSIDERED TO BE EFFECTIVE IN THE ACUTE PHASE OF LACUNAR INFARCTION.